Clinical, molecular, and functional biomarkers for prognosis, pathomechanisms, and treatment strategies in COVID-19

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:11 publications

Grant number: 01KI20160A

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

  • Research Location

    Germany, Europe
  • Lead Research Institution

    Charité - Universitätsmedizin Berlin
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



clinical trial - Infections with the novel Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) manifest with a broad spectrum of clinical presentations, ranging from asymptomatic to upper respiratory tract infections, uncomplicated pneumonia and severe pneumonia with respiratory failure and high lethality. Despite more than 1 Mio. documented infections worldwide, a profound lack of knowledge impedes clinical management and the development of therapies. COVID-19-associated pneumonia and lung injury differ in relevant details from any of the known types of pneumonia that cause respiratory failure, including viral infections like influenza or MERS-CoV. It is unclear whether specific decision guidelines established for pneumonia are applicable or whether these need to be refined for COVID-19. The PROVID consortium thus aims to characterize the host- and virus-dependent mechanisms associated with clinical appearance of COVID-19 to improve patient care through advances in risk stratification and clinical management. We will test the hypotheses that i) host factors (transcriptional response, proteins, antibodies) determine the severity and/or course of COVID-19, ii) molecular and clinical determinants of COVID-19 differ from those previously deciphered in other types of pneumonia and they can be used as molecular predictors for disease progression, iii) specific molecular markers of disease severity can be tested as therapeutic targets for COVID-19, iv) stabilization of barrier function - in addition to antivirals and immunomodulators - may present a third pillar for effective therapy.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Characterization of Commercially Available Human Primary Alveolar Epithelial Cells.

Ultrasonographic assessment of pulmonary and Central venous congestion in experimental heart failure.

Implementation of Recommendations for Features and Measurements of Experimental Acute Lung Injury.

Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.

MicroRNA-223 Dampens Pulmonary Inflammation during Pneumococcal Pneumonia.

Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.

Genetic Regulation of Cytokine Response in Patients with Acute Community-Acquired Pneumonia.

A proteomic survival predictor for COVID-19 patients in intensive care.

Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study.